Five Year Summary

All figures are in US$ million unless stated otherwise	2020-21 Constant Currency(1)	2020-21 Reported(2)	2019-20 Reported	2018-19 Reported	2017-18 Reported	2016-17 Reported
Total Operating Revenue	10,026	10,310	9,151	8,539	7,915	6,947
Sales Revenue	9,705	9,980	8,797	8,205	7,588	6,616
R&D Investment	969	1,001	922	832	702	667
Profit before Income Tax Expense	2,872	2,963	2,573	2,341	2,281	1,690
Net profit after tax	2,307	2,375	2,103	1,919	1,729	1,337
Net cash inflow from Operating Activities		3,622	2,448	1,644	1,902	1,247
Capital investment		1,667	1,367	1,285	992	861
Return on Invested Capital (%)		21.2	21.6	24.3	25.9	24.5
Basic earnings per share ($)		5.221	4.633	4.236	3.822	2.937
Dividend per share ($)		2.22	2.02	1.850	1.720	1.360

(1) Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further details please refer to CSL's Financial Statements for the Full Year ended 2021 (Directors' Report).
(2) The Group's reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(3) 2016 figure includes the gain on acquisition of Novartis' global influenza vaccine business of US$176.1 million.

Track our recent performance by year, region and major product group.

All figures are in US$ million unless stated otherwise	2019-20 Constant Currency(1)	2019-20 Reported(2)	2018-19 Reported	2017-18 Reported	2016-17 Reported	2015-16 Reported
Total Operating Revenue	9,295	9,151	8,539	7,915	6,947	6,115
Sales Revenue	8,938	8,797	8,205	7,588	6,616	5,909
R&D Investment	933	922	832	702	667	614
Profit before Income Tax Expense	2,741	2,573	2,341	2,281	1,690	1,556
Net profit after tax	2,247	2,103	1,919	1,729	1,337	1,242
Net cash inflow from Operating Activities		2,448	1,644	1,902	1,247	1,179
Capital investment		1,344	1,285	992	861	566
Return on Invested Capital (%)		21.6	24.3	25.9	24.5	26.8⁽³⁾
Basic earnings per share ($)		4.633	4.236	3.822	2.937	2.689
Dividend per share ($)		2.02	1.850	1.720	1.360	1.26

(1) Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further details please refer to CSL's Financial Statements for the Full Year ended 2019 (Directors' Report).
(2) The Group's reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(3) 2016 figure includes the gain on acquisition of Novartis' global influenza vaccine business of US$176.1 million.

2019/20 Annual Report

CSL reported net profit after tax was US$2,103 million for year ended 30 June 2020. On a constant currency basis, net profit after tax was US$2,247 million. Total ordinary dividends for the year were US$2.02 per share.

This browser is no longer supported

Five Year Summary

Track our recent performance by year, region and major product group.

2019/20 Annual Report

Introduction to CSL

Board and Management

Corporate Governance